1. Role of 18F-FDG-PET/CT in the staging of metastatic rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group
- Author
-
Gianni Bisogno, Federico Mercolini, Alison Cameron, J. Hans Merks, Timothy Rogers, Rick R. van Rijn, Beatrice Coppadoro, Nadège Corradini, Pietro Zucchetta, Julia C. Chisholm, Giovanni Scarzello, Soledad Gallego, Veronique Minard-Colin, Nina Jehanno, Radiology and Nuclear Medicine, and Other Research
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Staging ,18F-FDG-PET/CT ,Paediatric ,Rhabdomyosarcoma ,Child ,Child, Preschool ,Female ,Fluorodeoxyglucose F18 ,Humans ,Neoplasm Metastasis ,Neoplasm Staging ,Positron Emission Tomography Computed Tomography ,Retrospective Studies ,Sarcoma ,medicine ,Preschool ,Lymph node ,medicine.diagnostic_test ,business.industry ,Soft tissue sarcoma ,Bone metastasis ,Magnetic resonance imaging ,medicine.disease ,medicine.anatomical_structure ,Oncology ,Bone scintigraphy ,Positron emission tomography ,Bone marrow ,Radiology ,business - Abstract
Background Initial staging of rhabdomyosarcoma is crucial for prognosis and to tailor the treatment. The standard radiology workup (SRW) includes magnetic resonance imaging, chest computed tomography (CT) and bone scintigraphy, but 18 Fluorine-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) (18F-FDG-PET/CT (PET-CT)) use is increasing. The aim of this study was to evaluate the impact of PET-CT in the initial staging of patients with metastatic rhabdomyosarcoma enrolled in the European protocol MTS2008. Methods Two authors retrospectively reviewed the SRW and PET-CT reports comparing the number and sites of metastases detected. For bone marrow involvement, PET-CT and bone marrow aspirates/biopsies were compared. Results Among 263 metastatic patients enrolled from October 2008 to December 2016, 121 had PET-CT performed at diagnosis, and for 118 of 121 patients, both PET-CT and radiological reports were available for review. PET-CT showed higher sensitivity than SRW in the ability to detect locoregional (96.2% versus 78.5%, P value = 0.0013) and distant lymph node involvement (94.8% versus 79.3%, P value = 0.0242), but sensitivity was lower for intrathoracic sites (lung 79.6% versus 100%, P value = 0.0025). For bone metastasis, PET-CT was more sensitive than bone scintigraphy (96.4% versus 67.9%, P value = 0.0116). The PET-CT sensitivity and specificity to detect marrow involvement were 91.8% and 93.8%, respectively. The mean number of metastatic sites was 1.94 (range 0–5) with PET-CT and 1.72 (range 0–5) with SRW. In four patients (3.4%), PET-CT changed the staging from localised to metastatic disease. Conclusion PET can identify metastatic disease not evident on SRW in a small number of patients. This is because of its higher ability to recognise lymph node and bone involvement. Chest CT remains essential to detect lesions in intrathoracic sites, which can be performed in a one stop-shot routine examination or on a dedicated chest CT scan. PET-CT could replace bone scintigraphy to study bone involvement.
- Published
- 2021